Literature DB >> 35334082

Risk factors of herpes simplex virus reactivation after surgery for primary trigeminal neuralgia.

Xueke Zhen1, Xiaoli Xu1, Xu Shao1, Hong Tian1, Jun Xu1, Bin Zhu1, Ying Zuo1, Li Zhang1, Yanbing Yu2.   

Abstract

The objective of this study is to investigate the risk factors of oral or facial herpes simplex virus (HSV-1) infection after primary trigeminal neuralgia (PTN). The clinical data of 33 PTN patients admitted by the same surgeon in the neurosurgery were retrospectively analyzed. Among the 33 patients, 26 patients underwent microvascular decompression (MVD), 6 patients who have not been found the clear offending vessels during the operation underwent partial sensory rhizotomy (PSR), and only one underwent adhesive band separation. Thirteen patients with postoperative oral and facial HSV-1 infection were selected as the herpes group, and the remaining 20 patients without postoperative oral and facial HSV-1 infection were selected as the non-herpes group. The differences between the two groups were compared by statistical analysis of factors such as gender, age, operation mode, operation time, and serum HSV-1 antibody titer value before surgery. Compared with the non-herpes group, there were no statistically significant differences in sex ratio (P = 0.930), age composition (P = 0.261), or disease profile (P = 0.226). Twenty-six patients underwent MVD operation, eight of whom were infected, and the difference between the two groups was statistically significant (P = 0.029). The operation time of the herpes group was 10-30 min, which was significantly longer than that of the non-herpes group. The difference in operation time between the two groups was statistically significant (P = 0.023). Serum HSV-1-IgM was negative (< 0.9 COI) in all patients before surgery, but the positive rate of HSV-1-IgG (≥ 1.1 COI) was 97%, and the titer was greater than four times in 97% (32/33) of patients. The titer of IgG antibody in the herpes group was significantly lower than that in the non-herpes group, and the difference between the two groups was statistically significant (P = 0.017). The serum HSV-1-IgG in most of the PTN patients was positive. Latent HSV-1 in the trigeminal ganglion may be reactivate after PTN surgery to produce ipsilateral oral and facial herpes infection. The infection of HSV-1 reactivation after PTN surgery was positively correlated with the operation time but negatively correlated with the titer of HSV-1-IgG antibody before PTN surgery. The incidence of HSV-1 infection after PTN operation is related to different surgical procedures.
© 2022. Journal of NeuroVirology, Inc.

Entities:  

Keywords:  Antibody; Different surgical procedures; HSV-1; PTN; Risk factor

Mesh:

Substances:

Year:  2022        PMID: 35334082     DOI: 10.1007/s13365-022-01064-5

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   3.739


  7 in total

1.  Activation of latent herpes simplex by trigeminal sensory-root section.

Authors:  C A CARTON; E D KILBOURNE
Journal:  N Engl J Med       Date:  1952-01-31       Impact factor: 91.245

2.  Familial Trigeminal Neuralgia Cases Implicate Genetic Factors in Disease Pathogenesis.

Authors:  Shreyas Panchagnula; Agata K Sularz; Kristopher T Kahle
Journal:  JAMA Neurol       Date:  2019-01-01       Impact factor: 18.302

Review 3.  Occurrence of Herpes Simplex Virus Reactivation Suggests a Mechanism of Trigeminal Neuralgia Surgical Efficacy.

Authors:  Richard B Tenser
Journal:  World Neurosurg       Date:  2015-03-27       Impact factor: 2.104

4.  Herpes Simplex Reactivation After Surgical Treatment of Trigeminal Neuralgia: A Retrospective Cohort Study.

Authors:  Luigi Valentino Berra; Daniele Armocida; Alessandro Pesce; Andrea Di Rita; Antonio Santoro
Journal:  World Neurosurg       Date:  2019-02-13       Impact factor: 2.104

5.  Trigeminal neuralgia: a retrospective multicentre study of 320 Asian patients.

Authors:  Hans Prakash Sathasivam; Sumairi Ismail; Abdul Rahim Ahmad; Nor Nazaliza Basri; Hartinie Muhamad; Nur Fazilah Mohd Tahir; Chee Lynn Saw; Nurshaline Hj Kipli; Shin Hin Lau
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2016-08-17

6.  An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection.

Authors:  Kevin P Egan; Lauren M Hook; Alexis Naughton; Norbert Pardi; Sita Awasthi; Gary H Cohen; Drew Weissman; Harvey M Friedman
Journal:  PLoS Pathog       Date:  2020-07-27       Impact factor: 6.823

7.  Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis.

Authors:  Shan K Naidu; Rafiq Nabi; Nagarjuna R Cheemarla; Brent A Stanfield; Paul J Rider; Nithya Jambunathan; Vladimir N Chouljenko; Renee Carter; Fabio Del Piero; Ingeborg Langohr; Konstantin G Kousoulas
Journal:  PLoS One       Date:  2020-02-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.